MRI device developer Biophan Technologies of West Henrietta, NY, has launched an animal trial to test a new vena cava filter that can be visualized under MR imaging.
Vena cava filters are used to prevent lung embolisms by trapping circulating blood clots, plaque, or other materials. In current clinical practice, the filters are mainly inserted through the femoral vein, and placed in the inferior vena cava under x-ray guidance. Biophan believes that placing the filters under MRI guidance would be a less invasive alternative to x-ray guided filters.
The company plans to begin testing the filters in pigs in studies conducted in cooperation with the University of Essen and the University of Aachen, both in Germany. The filter is being developed by the company's Biophan Europe subsidiary in Germany, which previously was known as AMRIS until Biophan acquired the company earlier this year.
By AuntMinnie.com staff writers
March 14, 2005
Related Reading
Biophan bids for German device firm, January 7, 2005
Biophan names Shellock to advisory board, September 28, 2004
Biophan nets MRI-guided surgery patent rights, August 10, 2004
Biophan lands funding commitment, February 9, 2004
Biophan joins forces with Boston Scientific, November 5, 2003
Copyright © 2005 AuntMinnie.com
